ABSTRACT
Acute supraglottitis is a medical emergency as it can rapidly lead to airway compromise. With routine pediatric immunization for Hemophilus influenzae serotype b, supraglottitis is now more prevalent in adults, with a shift in the causative organisms and a change in the natural history of this disease. Here, we present a case of supraglottitis due to group B streptococcus that occurred in an adult with previously undetected immunoglobulin 4 (IgG4) and complement protein C2 deficiency.
Subject(s)
Immunocompromised Host/immunology , Streptococcal Infections/diagnosis , Streptococcus agalactiae/isolation & purification , Supraglottitis/immunology , Supraglottitis/microbiology , Adrenal Cortex Hormones/therapeutic use , Adult , Anti-Bacterial Agents/therapeutic use , Complement C2/deficiency , Complement C2/immunology , Emergency Service, Hospital , Follow-Up Studies , Humans , IgG Deficiency/immunology , Male , Rare Diseases , Risk Assessment , Severity of Illness Index , Streptococcal Infections/drug therapy , Supraglottitis/diagnosis , Supraglottitis/drug therapy , Treatment OutcomeABSTRACT
BACKGROUND: The lung is the most common site for primary cancer worldwide as well as being a common site of metastases for various malignancies. Percutaneous radiofrequency ablation (RFA) is rapidly evolving as a new minimally invasive tool for the treatment of pulmonary tumors. PATIENTS AND METHODS: A questionnaire was sent by e-mail to 14 centres around the world, which we knew or thought were performing percutaneous pulmonary RFA, to retrospectively survey their experience in this field including the number of ablations done to date, indications, method, peri- and postprocedural complications. RESULTS: Seven centers reported 493 percutaneous procedures in lung tumors. Two deaths have been reported. Complications were subdivided into major and minor complications. Pneumothorax occurred in up to 30% of interventions with less than 10% requiring intercostal drainage. Pleural effusion requiring aspiration occurred in less than 10% of cases. CONCLUSION: With almost 500 procedures done to date, percutaneous pulmonary RFA appears to be a safe, minimally invasive tool for local pulmonary tumor control with negligible mortality, little morbidity, short hospital stay and gain in quality of life.
